This site contains material about Vyera Pharmaceuticals, LLC ("Vyera") and its various products that may be of interest to Vyera's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Vyera.
Vyera maintains this web site for your personal use. This web site and its contents are intended to comply with the laws and regulations of the U.S. While you can access this web site from outside the U.S., our server is located within the U.S., and the web site it is intended to be used by residents located in the U.S. Nothing in this website should be interpreted as a promotion or solicitation for any product that is not authorized by the laws and regulation of the country where the visitor is located.
Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Vyera. Not all products or indications are licensed in every country and may be subject to further local variations.
While there may be information on this web site related to certain medical conditions and their treatment, should a medical condition exist, promptly see your own physician or health provider. Vyera does not offer individual or personalized medical diagnosis or patient-specific treatment advice. Indeed, only your doctor or other health care professional, as a learned intermediary, can determine if a product described in this web site is appropriate for you.
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This web site and all the materials published by Vyera on this website are copyright protected. Any textual or graphic material you copy, print, or download from this web site is licensed to you by Vyera and/or its subsidiaries for your personal, noncommercial home use only, provided that you do not change or delete any copyright, trademark or other proprietary notices. Nothing contained in this web site shall be construed as conferring on you any license or right under any copyright, patent or trademark of Eisai, its parent or affiliates, or any third party, whether by implication, estoppel or otherwise. Except as expressly provided above, nothing contained in this web site shall be construed as conferring any license or right under any Vyera copyright.
Vyera will use reasonable efforts to include accurate, complete and up-to-date information on this web site, but Vyera makes no warranties or representations as to its accuracy, completeness or frequency that it is updated. All users agree that access to this web site is at their own risk, and that neither Vyera nor any party involved in creating or delivering this web site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if Vyera has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this web site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this web site. This limitation includes damages to, or for any viruses that may infect, your computer equipment.
All legal disputes arising out of or in connection with this web site (including without limitation, disputes regarding usage of personal information provided to Vyera via the web site) which cannot be resolved through good faith discussions, shall be referred to and finally determined by arbitration as follows. The Arbitration Tribunal shall comprise three arbitrators. Each party shall appoint one arbitrator and the two arbitrators so appointed shall appoint the third arbitrator. The third arbitrator shall be a member of the legal profession. If either party fails to appoint its arbitrator within one month of the receipt of a corresponding request by the other, or if the two arbitrators appointed fail to reach agreement on the third arbitrator within one month of the date of the last appointment, that arbitrator and/or the third arbitrator shall, at the request of either party, be appointed by the American Arbitration Association. The Arbitration Tribunal shall sit in New York, New York and the arbitration proceedings shall be conducted in English. The arbitration proceedings shall be governed by the rules of civil procedure applicable in the State of New York.
Information and related materials are subject to change without notice. This web site, and all information and related materials it contains, are provided "as is." Vyera makes no representation or warranty whatsoever regarding the completeness, accuracy, "up-to-dateness", or adequacy of, or the suitability, functionality, availability, or operation of this web site or the information or materials it contains. By using this web site, you assume the risk that the information and materials on this web site may be incomplete, inaccurate, out of date, or may not meet your needs and requirements. Vyera specifically disclaims all warranties, express or implied, including without limitation, the warranties or merchantability, fitness for a particular purpose, and non-infringement with respect to this web site and information, graphics and materials contained herein.
This web site may contain links to, or be accessed from links on, other World Wide Web sites. Vyera does not have responsibility for, or control of, the contents, availability, operation or performance of other web sites to which this web site may be linked or from which this web site may be accessed. Vyera makes no representation regarding the content of any other web sites which you may access from this web site
All trademarks, logos and service marks (collectively “Trademarks”) appearing in this web site, and as designated with either a trademark symbol or type form that is different from the surrounding text, are trademarks owned by or licensed to Vyera, its subsidiaries or affiliates. Notwithstanding this disclaimer, all other names and marks mentioned in this web site are the trade names, trademarks or service marks of their respective owners. The use or misuse of these Trademarks or any other materials, except as permitted herein, is expressly prohibited and may be in violation of the laws of copyright, trademark, privacy, publicity, slander, libel and communications.
Nothing in this web site shall be construed as conferring by implication, estoppel or otherwise, any license or right to use in any form or manner any patent, copyright or trademark of Vyera. Please be advised that Vyera protects its intellectual property rights to the fullest extent of the law.
The submission of any unsolicited information, such as questions, comments, or suggestions, to Vyera, either through this web site or by any other means of communication, shall NOT be considered confidential. Vyera shall have no obligation to you of any kind with respect to such information. By submitting any information to Vyera, you understand that Vyera shall be free to reproduce, use, disclose, display, exhibit, transmit, perform, create derivative works, and distribute the information to others without limitation, and to authorize others to do the same. In addition, Vyera shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever, including but not limited to, developing, manufacVyera and marketing products and other items incorporating such ideas, concepts, know-how or techniques.
This agreement shall be governed by and construed in accordance with laws of the U.S. If any provision of this agreement is held to be unlawful, void, or for any reason unenforceable, then that provision shall be eliminated or limited to the minimum extent necessary and such elimination or limitation shall not affect the validity and enforceability of any remaining provisions. This is the entire agreement between the parties relating to the subject matter herein and you agree to indemnify Vyera for any claims or damages resulting from your failure to abide by these terms and conditions.
The Vyera web site may be unavailable from time to time due to mechanical, telecommunication, software, hardware and third-party vendor failures, updating or construction. Vyera cannot predict or control when such downtime may occur and cannot control the duration of such downtime.
Vyera reserves the right to alter or delete material from this web site at any time.
Vyera may, at any time, revise these Web site Usage Terms by updating this posting. You are bound by any such revisions and should, therefore, periodically review these terms to review the then current Usage Terms.
VECAMYL (mecamylamine hydrochloride 25 mg tablet) - IMPORTANT SAFETY INFORMATION
VECAMYL should not be used in patients with mild, moderate, labile hypertension and may prove unsuitable in uncooperative patients. It should also not be given to patients with coronary insufficiency or recent myocardial infarction.
VECAMYL is contraindicated for patients with uremia, and should be used with caution in patients with renal insufficiency revealed by elevated BUN.
In general, patients receiving antibiotics and sulfonamides should not be treated with VECAMYL.
VECAMYL is also contraindicated for patients with glaucoma, organic pyloric stenosis, or hypersensitivity to mecamylamine hydrochloride.
Tremor, choreiform movements, mental aberrations, and convulsions may occur rarely due to the ability of mecamylamine to readily penetrate into the brain and consequently cause central nervous system effects. These effects have occurred most often following large doses of VECAMYL, particularly in patients with cerebral or renal insufficiency.
When discontinuing VECAMYL, the drug should be withdrawn gradually and other antihypertensive therapy usually must be substituted. Sudden discontinuation of VECAMYL can cause hypertension to abruptly return, which in certain patients, for example those with malignant hypertension, may cause fatal cerebral events or acute congestive heart failure. The effects of VECAMYL may last for hours to days after stopping therapy.
Prior to prescribing VECAMYL, a patient's condition should be evaluated, particularly with respect to renal and cardiovascular function. Additional impairment resulting from hypotension in patients deficient in renal, cerebral, or coronary blood flow must be avoided. VECAMYL should be used with caution in patients with marked cerebral and coronary arteriosclerosis or who have had a recent cerebral vascular accident.
The action of VECAMYL may be potentiated by excessive heat, fever, infection, hemorrhage, pregnancy, anesthesia, surgery, vigorous exercise, other antihypertensive drugs, alcohol, and salt depletion due to diminished salt intake or increased salt excretion as a result of diarrhea, vomiting, excessive sweating, or diuretics.
Patients with prostatic hypertrophy, bladder neck obstruction, or urethral stricture should be treated with caution since urinary retention may occur with VECAMYL.
VECAMYL should immediately be discontinued and remedial steps taken if a patient has signs of paralytic ileus, such as frequent loose bowel movements with abdominal distention and decreased borborygmi.
Patients receiving antibiotics and sulfonamides generally should not be treated with VECAMYL.
The action of VECAMYL may be potentiated by anesthesia, other antihypertensive drugs, and alcohol.
VECAMYL is a potent, oral antihypertension agent and ganglion blocker.
VECAMYL is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.
You are about to enter a site that is for US healthcare professionals only. By clicking “Confirm” below, you certify that you are a healthcare professional and that you wish to proceed to the Healthcare Professionals Only section of this site. Products or treatments described on this site are available in the US but may not be available in other countries.
I am a licensed healthcare professional and wish to proceed to the Healthcare Professionals section of this site.Confirm